Kyowa Hakko Enters Antibody Space With Alnylam RNAi RSV Therapy

TOKYO - In its quest to expand into the antibody therapy area, Kyowa Hakko Kogyo signed a license contract for marketing Alnylam's respiratory syncytial virus injection drug in Japan and East Asian countries, a Kyowa Hakko spokesman confirmed June 23